Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c

ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update

November 2, 2020 4:01 PM EST

 Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets

 U.S. Product Revenue Increased Five-fold During the Third Quarter

 ESPERION Partner Daiichi Sankyo Europe Launches NILEMDO (bempedoic acid) and NUSTENDI (bempedoic acid and ezetimibe) in Germany, the Largest European Market

Conference Call and Webcast today, November 2nd at 4:30 P.M. Eastern Time

ANN ARBOR, Mich., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2020, and... More